NCT02003495

Immunogenicity and Safety of Meningococcal (A, C, Y and W135) Conjugate Vaccine

Immunogenicity and Safety of Meningococcal (A, C, Y and W135) Conjugate Vaccine in Healthy Subjects 2 Months to 6 Years of Age in China

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 2,195 (actual)
• Sponsor: Beijing Minhai Biotechnology Co., Ltd · Industry
• Sex: All
• Age: 2 Months – 6 Years
• Healthy volunteers: Accepted

Summary

The purpose of this observer-blind study is to evaluate the safety, reactogenicity and immunogenicity of Meninggococcal (A,C,Y and W135) Conjugate Vaccine in 2 months to 6 years-old children.

Conditions

• Meningitis

Interventions

Type	Name	Description
BIOLOGICAL	MCV-ACYW135 Vaccine Group	0.5ml, intramuscular
BIOLOGICAL	MPV-ACYW135 Vaccine Group	0.5ml, intramuscular
BIOLOGICAL	MPV-A Vaccine Group	0.5ml, intramuscular
BIOLOGICAL	MCV-AC Vaccine Group	0.5ml, intramuscular
BIOLOGICAL	Hib Vaccine Group	0.5ml, intramuscular

Timeline

• Start date: 2013-10-01
• Primary completion: 2014-08-01
• Completion: 2014-10-01
• First posted: 2013-12-06
• Last updated: 2015-09-22

Locations

1 site across 1 country: China